Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539141 | 0.98 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16922341 | 0.96 | LPL (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16611249 | 0.89 | LPL (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL138606 | 0.88 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16685004 | 0.86 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19583 | 0.86 | ALDH1A1 (0.49) | LPLLIPGMAPTKDM4EALDH1A1 | |
| SCHEMBL24266350 | 0.85 | L3MBTL3 (0.61) | LPLLIPGL3MBTL1 | |
| SCHEMBL20644595 | 0.85 | MAPT (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20644510 | 0.85 | LPL (0.65) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15788150 | 0.85 | LPL (0.45) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250212681-A1 | Light-Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-06-26 | — | — | US | disclosed |
| US-20250126968-A1 | Light-Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250101027-A1 | ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, AND ELECTRONIC APPLIANCE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| WO-2024255790-A1 | FUSED RING COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2502909-A1 | AMINOPYRIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2348857-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010047982-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101027-A1 | ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, AND ELECTRONIC APPLIANCE | RER1, OLA1, CRY1 | LPL 2393/4885LIPG 3695/4885CA1 3490/4885 |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | LPL 1985/4885LIPG 2901/4885CA1 4270/4885 |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | LPL 1919/4885LIPG 723/4885CA1 3839/4885 |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | LPL 402/4885LIPG 287/4885CA1 4866/4885 |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | DCX, NR0B1, NR4A1 | LPL 4797/4885LIPG 4860/4885CA1 1760/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | LPL 4483/4885LIPG 4184/4885CA1 4187/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | LPL 402/4885LIPG 287/4885CA1 4866/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | LPL 340/4885LIPG 247/4885CA1 4253/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | LPL 3952/4885LIPG 3807/4885CA1 3067/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LPL 1419/4885LIPG 768/4885CA1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.